Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Investment Type: Venture Capital
Portfolio 3
| Date | Name | Website | Total Raised | Location |
| 02.04.2026 | StairMed | stairmed.com | $500M | - |
| 22.09.2025 | Avenzo The... | avenzotx.com | $210M | United Sta... |
| 06.09.2025 | Ronovo Sur... | ronovosurgical.com | $161M | China |
Mentions in press and media 23
| Date | Title | Description |
| 19.05.2026 | Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases | Financing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and Oriza Proceeds will advance multi-asset pipeline including AC-101, a leading RIPK2 inhibitor for Ulcerative Colitis NEW YORK and SUZH... |
| 25.04.2026 | Pulnovo Medical: $100 Million Financing Round Led By Medtronic Closed | Pulnovo Medical, a New York-based pioneer in breakthrough therapies for pulmonary hypertension and heart failure, has completed an oversubscribed $100 million strategic financing round led by Medtronic, one of the world’s largest medical te... |
| 20.04.2026 | Pulnovo Medical Raises $100M in Funding | Pulnovo Medical, a NYC-based developer of therapies for treating pulmonary hypertension and heart failure, raised $100M in funding. The round was led by Medtronic, with participation from existing investors such as EQT, Qiming Venture Partn... |
| 03.04.2026 | China's BMI Frontier: StairMed Fuels Next-Gen Human-Machine Integration | StairMed secured RMB 500 million ($69M) from Alibaba, Tencent, and others. This investment accelerates brain-machine interface (BMI) and neuromodulation development. The company progresses 256-channel BMI clinical trials in China, pioneerin... |
| 02.04.2026 | CHIC 2026 Honors Landmark Deals and Financings at Annual Awards Gala | SHANGHAI, April 2, 2026 /PRNewswire/ -- The 12th Annual China Healthcare Investment Conference (CHIC 2026) capped the first day of its two-day program with a celebratory Awards Gala Dinner held at The Ritz-Carlton Hotel Pudong, Shanghai. Th... |
| 02.04.2026 | StairMed: RMB 500 Million (About $69 Million) Raised For Brain Machine Interface Development | Shanghai-based StairMed has secured RMB 500 million in a new financing round led by Alibaba, with participation from existing investors including Tencent, Fountainbridge Capital, OrbiMed, Oriza Seed, Qiming Venture Partners, Lilly Asia Vent... |
| 22.03.2026 | Excalipoint Therapeutics Secures $68.7M for Next-Gen TCE Therapies | Excalipoint Therapeutics, a dynamic Shanghai-based biotechnology firm, secured $68.7 million in oversubscribed seed funding. This substantial capital propels its mission to redefine T-cell engager (TCE) therapies. The company is tackling si... |
| 18.03.2026 | Excalipoint Therapeutics: $68.7 Million Raised For Next-Generation T-Cell Engager Therapies | Excalipoint Therapeutics, a clinical-stage biotechnology company focused on next-generation T-cell engager therapies, announced the close of an oversubscribed $68.7 million seed financing round to advance its proprietary platforms and pipel... |
| 13.03.2026 | Alibaba leads RMB 500 million investment in BCI startup StairMed | StairMed, a brain-computer interface (BCI) developer, has secured RMB 500 million (USD 72.7 million) in a funding round led by Alibaba Group, with participation from SDIC Unity Capital. Existing investors including Tencent, FountainBridge C... |
| 17.11.2025 | Chinese Drugmakers Rush to List in Hong Kong Amid Strong Investor Interest | (Yicai) Nov. 17 -- Chinese drugmakers are flocking to list in Hong Kong this year, driven by strong investor interest, recent stock market gains, overseas licensing deals, and regulatory reforms, though cornerstone investors are becoming mo... |
Show more